TB-PRACTECAL: Efficacy and Safety of Three 24-Wk Oral Regimens for Pulmonary Rifampicin-Resistant TB in Persons With HIV

Source: CCO Official Conference Coverage: Clinical Impact of New HIV Data From AIDS 2022
Download Slideset
July 29-August 2, 2022; Montreal, Quebec
Bedaquiline, pretomanid, and linezolid with or without clofazimine or moxifloxacin for 24 weeks appeared to be generally safe and effective for the treatment of rifampicin-resistant TB in both people with and without HIV in this randomized, open-label phase II/III trial.
Format: Microsoft PowerPoint (.ppt)
File Size: 275 KB
Released: August 4, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings